Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic HNSCC

Next Previous
Trial Profile

A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic HNSCC

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CUE 101 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms KEYNOTE' KN-A78; KEYNOTE-A78
  • Sponsors Cue Biopharma

Most Recent Events

  • 16 Jul 2025 Results presented in the Cue Biopharma Media Release.
  • 01 Jul 2025 Results presented in a Cue Biopharma media release.
  • 01 Jul 2025 According to Cue Biopharma media release, data from this were presented at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top